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Abstract
In patients with hyperdynamic hemodynamics, infusing arginine
vasopressin (AVP) in advanced vasodilatory shock is usually
accompanied by a decrease in cardiac output and in visceral organ
blood flow. Depending on the infusion rate, this vasoconstriction
also reduces coronary blood flow despite an increased coronary
perfusion pressure. In a porcine model of transitory myocardial
ischemia-induced left ventricular dysfunction, Müller and
colleagues now report that the AVP-related coronary vaso-
constriction may impede diastolic relaxation while systolic contrac-
tion remains unaffected. Although any AVP-induced myocardial
ischemia undoubtedly is a crucial safety issue, these findings need
to be discussed in the context of the model design, the dosing of
AVP as well as the complex direct, afterload-independent and
systemic, vasoconstriction-related effects on the heart.
In the previous issue of Critical Care Müller and colleagues
reported that arginine vasopressin (AVP) (either 0.005 U/kg/min
or titrated to a mean arterial pressure of 90 mmHg) after
porcine myocardial ischemia reduced the cardiac output and
the brain, coronary and kidney blood flow [1]. The fall in blood
flow was compensated for by a marked increase in oxygen
extraction. In particular, while left heart systolic contraction
was not affected, AVP impaired diastolic relaxation and
ventricular compliance. Neither the ischemic period nor the
subsequent AVP infusion influenced the plasma troponin T
level. The authors conclude that using AVP should be
cautioned during cardiac surgery and AVP should be
withheld in ischemic heart failure.
How does Müller and colleagues’ study compare with the
existing literature? The observed cerebral and renal vaso-
constriction confirms findings by Malay and colleagues: incre-
mental AVP – similar to the pure α-agonist phenylephrine –
dose-dependently reduced organ blood flow [2]. Müller and
colleagues unfortunately did not measure portal venous flow,
but it is tempting to speculate that the increased hepatic
arterial flow reflects a well-maintained hepatic arterial buffer
response, which at least partially compensated for the most
likely reduced portal venous flow. In fact, low doses of the
AVP analogue terlipressin during long-term, hyperdynamic
porcine endotoxemia restored this otherwise impaired
physiologic adaptation [3].
The myocardial effects reported by Müller and colleagues
deserve particular attention: in good agreement with their
results, ample literature is available that the dose-dependent
vasoconstrictor properties of AVP are also present in the
coronary circulation [4-8]. Nevertheless, direct afterload-
independent (that is, unrelated to systemic vasoconstriction)
myocardial effects of AVP are a matter for debate: both
positive inotrope properties [6,9] and negative inotrope
properties [4,8,10,11] have been reported in isolated heart,
papillary muscle or cardiomyocyte preparations. Furthermore,
it remains unsettled whether any negative inotrope effect is
mainly caused by the reduced coronary perfusion [7],
because cardiac efficiency (that is, the product of left
ventricular pressure times the heart rate normalized for
myocardial oxygen consumption) was well maintained under
constant flow conditions [12]. The present data do not allow
one to conclude whether the impaired diastolic relaxation is
afterload dependent or is a genuine myocardial effect:
unfortunately, the authors did not perform experiments using
other pure vasoconstrictors, – for example, pure α-adreno-
ceptor agonists or KATP channel blockers devoid of cardiac
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and mitochondrial effects, titrated to the same systemic
hemodynamic endpoints.
What do we learn from Müller and colleagues’ findings? In
this context, the experimental design must be taken into
account. The model per se is hypodynamic (that is, charac-
terized by hypotension and a simultaneous fall in cardiac
output resulting from ischemic heart failure), and thus differs
from the hyperdynamic, vasodilatory circulation in patients
usually treated with AVP [13]. In addition, the current
rationale of AVP use comprises a supplemental infusion,
targeted to restore vasopressin levels to those comparable
with other causes of hypotension, and presents AVP
simultaneously with catecholamines rather than using AVP
alone [13]. In fact, we found during long-term, resuscitated
hyperdynamic porcine fecal peritonitis that combining
noradrenaline with AVP to maintain baseline blood pressure
did not affect the heart rate-independent parameters of left
ventricular systolic and diastolic function, and that the
combination coincided with significantly lower plasma
troponin I levels than treatment with noradrenaline alone
(Hauser B, Giudici R, Simon F, Nguyen CD, Radermacher P,
Calzia E, unpublished data).
Furthermore, although Müller and colleagues used the lowest
infusion rate necessary to restore blood pressure, it was still
substantially higher than that considered safe by others [2,13]
and used in the Vasopressin in Septic Shock Trial [14]. It is
noteworthy that this low dose of AVP was associated with, if
any, beneficial effects on parameters of myocardial function
and/or injury: in a retrospective, uncontrolled study, Dünser
and colleagues observed a time-dependent fall of troponin I
levels in patients treated for catecholamine-resistant
vasodilatory shock after cardiotomy [15]; and in a prospective,
randomized, controlled study investigating a mixed intensive
care unit population, the same group found a markedly
reduced incidence of new-onset tachyarrhythmias in patients
treated with AVP and noradrenaline compared with those
patients receiving noradrenaline alone [16].
What can we conclude on the clinical use of AVP? The rate
of adverse events in the Vasopressin in Septic Shock Trial
was similar in the two populations with and without
vasopressin infusion, but patients with underlying heart
disease were not enrolled [14]. Any safety issue potentially
limiting the clinical use of AVP therefore remains a matter of
concern. Given its vasoconstrictor properties, which are not
accompanied by positive inotropic qualities such as in the
case of comparably potent standard care competitors (that is,
the catecholamines noradrenaline and adrenaline), AVP may
depress cardiac function as a result of impaired coronary
blood flow despite increased coronary artery perfusion
pressure. Consequently, as Müller and colleagues conclude,
and despite encouraging case reports [17], the use of AVP
should be cautioned during cardiogenic shock resulting from
congestive heart failure and/or myocardial ischemia.
It is noteworthy that despite only short-term symptomatic
improvement and the neutral long-term results of the Efficacy
of Vasopressin Antagonism in Heart Failure Outcome Study
using tolvaptan, AVP receptor blockade is still under
investigation in patients with congestive heart failure [18]. A
recent comment in Critical Care is therefore more valid than
ever: ‘Vasopressin in vasodilatory shock: ensure organ blood
flow, and take care of the heart!’ [19].
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